[
    [
        {
            "time": "",
            "original_text": "【华泰医药代雯团队】安图生物（603658）化学发光高增长，业绩符合预期",
            "features": {
                "keywords": [
                    "安图生物",
                    "化学发光",
                    "高增长",
                    "业绩",
                    "符合预期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【华泰医药代雯团队】安图生物（603658）化学发光高增长，业绩符合预期",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【安图生物】年报点评：化学发光行业将迎来分化，龙头业绩持续较高增长",
            "features": {
                "keywords": [
                    "安图生物",
                    "年报",
                    "化学发光",
                    "行业分化",
                    "龙头",
                    "业绩",
                    "较高增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【安图生物】年报点评：化学发光行业将迎来分化，龙头业绩持续较高增长",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "安图生物去年净利润5.63亿元 同比增长26% 董事长苗拥军年薪为106万元",
            "features": {
                "keywords": [
                    "安图生物",
                    "净利润",
                    "同比增长",
                    "26%",
                    "董事长",
                    "年薪"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安图生物去年净利润5.63亿元 同比增长26% 董事长苗拥军年薪为106万元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "安图生物：业绩稳健增长，免疫诊断产品持续实现突破",
            "features": {
                "keywords": [
                    "安图生物",
                    "业绩",
                    "稳健增长",
                    "免疫诊断",
                    "产品突破"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安图生物：业绩稳健增长，免疫诊断产品持续实现突破",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "安图生物:发光带动业绩持续增长,多产品线布局日趋完善",
            "features": {
                "keywords": [
                    "安图生物",
                    "发光",
                    "业绩",
                    "持续增长",
                    "多产品线",
                    "布局完善"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安图生物:发光带动业绩持续增长,多产品线布局日趋完善",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "安图生物:业绩增速稳定,业务不断丰富",
            "features": {
                "keywords": [
                    "安图生物",
                    "业绩",
                    "增速稳定",
                    "业务",
                    "丰富"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安图生物:业绩增速稳定,业务不断丰富",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]